Proteon Therapeutics (PRTO) Reports Q2 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Proteon Therapeutics (PRTO) Reports Q2 Loss of $0.31/Share
August 13, 2015 5:15 PM EDT
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended June 30, 2015, and recent business highlights.
"I am pleased that the first Phase 3 clinical study of vonapanitase is on track to complete enrollment by the end of the year and that we recently enrolled our first patient in our second Phase 3 clinical study of vonapanitase," said Timothy Noyes, President and Chief Executive Officer of Proteon.
... More
August 13, 2015 5:15 PM EDT
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended June 30, 2015, and recent business highlights.
"I am pleased that the first Phase 3 clinical study of vonapanitase is on track to complete enrollment by the end of the year and that we recently enrolled our first patient in our second Phase 3 clinical study of vonapanitase," said Timothy Noyes, President and Chief Executive Officer of Proteon.
... More
